about
Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancersAntibody-drug conjugates as novel anti-cancer chemotherapeuticsDevelopment of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Mining human antibody repertoires.Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.Overview on the use of therapeutic antibodies in drug discovery.Passive antibody administration (immediate immunity) as a specific defense against biological weapons.Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.Antibody-based therapeutics in oncology.Biologic therapies: what and when?IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.Idiotypic networks: toward a renaissance?Probabilities of success for antibody therapeutics.Supplementation of Nucleosides During Selection Can Reduce Sequence Variant Levels in CHO Cells Using GS/MSX Selection System.Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.Immunology at the crossroads. As decades of research have resulted in few clinical applications, it is time to think about new research strategies to understand the workings of the immune system.Equipment characterization to mitigate risks during transfers of cell culture manufacturing processes.Online integrity monitoring in the protein A step of mAb production processes-increasing reliability and process robustness.Implementing high-temperature short-time media treatment in commercial-scale cell culture manufacturing processes.Metrics for antibody therapeutics development.Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA.4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.As Technologies for Nucleotide Therapeutics Mature, Products Emerge.Evaluation of heavy chain C-terminal deletions on productivity and product quality of monoclonal antibodies in Chinese hamster ovary (CHO) cells.Next-generation protein drugs.Optimizing capacity utilization by large scale 3000 L perfusion in seed train bioreactors.Comparison of the chromatographic properties of IgG1 and IgG2 antibody subclasses.Mechanism of antibody reduction in cell culture production processes.Two-dimensional difference fluorescence gel electrophoresis to verify the scale-up of a non-affinity-based downstream process for isolation of a therapeutic recombinant antibody.Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectinTherapeutic Antibodies - from Past to Future
P2860
Q24792155-491D2C01-4FF2-46ED-911B-CC4A2BD6DC5EQ26800175-4633D00E-BF51-4CF2-AE58-19C4DC4E3D26Q33301860-E9217122-0FF7-41B3-BB38-A6FE5B800BA1Q33588489-EEA99FEB-CF55-4857-9253-B5CC859F4BD9Q34038244-5996A81E-A19D-47D7-8EFB-A0001EE66C3BQ34147273-C8D9F0A2-F35B-4712-927D-3030C72D06B2Q34762095-AE028D62-3ABD-4CEF-B0F8-63B549A45418Q34983092-8819ACA1-D737-4DC9-9154-EA54FF6CCB7DQ35070445-C2889C47-174E-499C-AB9E-B7FA88368883Q35770607-F3DA21FF-D38F-4F0F-9225-D3A8018957C1Q35992493-9B174E73-7068-4B3D-9813-7E444CFCD896Q36453638-501FAA9A-D61C-4238-B7CE-457EC92DA886Q36762532-85A01808-228E-48FF-9784-9D9A7ABA41C4Q37304479-5579674D-17CB-497B-8DDB-FB32063695AFQ38660695-8884940A-E544-4D56-A12C-CDDA9B376EEEQ40331204-AE0AB942-B64B-4969-8DF2-34F5AA8D4442Q40398587-4CCCFD91-8FDE-4D16-ABD6-A6CB9FAB750EQ40671988-BF993737-B3D3-40FD-B2A2-A4AAFD890056Q42246257-03D2E705-E5AA-4D4D-A06D-88A330FBB25EQ42247564-32693CC6-8441-4422-8C94-07453A0C867FQ42556144-00F1E936-8FD2-43C0-81BC-33C9691A97A6Q42557601-722884E4-0F46-473F-86D2-DE9C2A9E14D6Q43070193-28C434D7-FCA8-45D0-BF28-20A89158EFB5Q43072108-6DF21708-98E1-48C7-884A-C7AE3E7D6AFAQ47131796-B539E38F-9262-4FF4-9267-AF94A8F8F6C1Q47439837-CEAAE27F-1364-4D05-B132-B883713871E4Q47662250-4CAB754D-F85F-49BB-9A77-74EDD71EA225Q51755750-AF58FEAD-8DAF-432C-AFD5-5290F007DDCAQ51771638-D15AE1E4-E7D2-444C-8505-F17FAE0E5A79Q51772982-0D76AF72-A49D-46AC-8573-1B85E5827A1EQ51773462-4F7D6558-F048-4D0D-9C7C-F83D11280C78Q57912156-495FC288-AA8D-407C-9FC3-CAD8E5BE4BD4Q58008023-690424B7-84DB-403B-A9D7-AADB71822D31
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Monoclonal antibodies in the clinic.
@ast
Monoclonal antibodies in the clinic.
@en
Monoclonal antibodies in the clinic.
@nl
type
label
Monoclonal antibodies in the clinic.
@ast
Monoclonal antibodies in the clinic.
@en
Monoclonal antibodies in the clinic.
@nl
prefLabel
Monoclonal antibodies in the clinic.
@ast
Monoclonal antibodies in the clinic.
@en
Monoclonal antibodies in the clinic.
@nl
P356
P1433
P1476
Monoclonal antibodies in the clinic
@en
P2093
Reichert JM
P2888
P304
P356
10.1038/NBT0901-819
P577
2001-09-01T00:00:00Z